［1］Shi JF，Canfell K，Lew JB，et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China：an epidemiologic and cost-effectiveness modelling study. BMC Cancer，2011，11（1）：239.

［2］World Health Organization. National cancer control programmes：policies and managerial guidelines. 2nd ed. Geneva Switlannd，2002.

［3］中华人民共和国卫生部.中国癌症预防与控制规划纲要（2004—2010）. 2003.

［4］Pepe MS，Etzioni R，Feng ZD，et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst，2001，93（14）：1054-1061.

［5］Greenwald P，Cullen JW，Weed D. Cancer prevention and control. Semin Oncol，1990，17（4）：383-390.

［6］Pepe MS，Feng DZ，Janes H，et al Pivotal evaluation of the accuracy of a biomarker used for classification or prediction：standards for study design. J Natl Cancer Inst，2008，100：1432-1438.

［7］Croswell JM，Ransohoff DF，Kramer BS. Principles of cancer screening：lessons from history and study design issues. Semin Oncol，2010，37（3）：202-215.

［8］David Schottenfeld，Joseph F. Fraumeni. Cancer Epidemiology and Prevention. 3rd edition. Oxford University Press，2006.

［9］Kenneth J. Rothman，Sander Greenland. Modern Epidemiology. Lippincott-Raven Publishers. 2nd ed. Philadelphia，PA，USA，1998.

［10］Fields RP. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med，2008，358（6）：642-643.

［11］Katki HA，Kinney WK，Fetterman B，et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology：a population-based study in routine clinical practice. Lancet Oncol，2011，12（7）：663-672.

［12］Connor RJ，Prorok PC，Weed DL. The case-control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol. 1991，44（11）：1215-1221.

［13］Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol，1992，14（2）：117-128.

［14］Etzioni RD，Connor RJ，Porok PC，et al. Design and analysis of cancer screening trials. Stat Methods Med Res，1995，4（1）：3-17.

［15］Weiss NS，Dhillon PK，Etzioni R. Case-control studies of the efficacy of cancer screening：overcoming bias from nonrandom patterns of screening. Epidemiology，2004，15（4）：409-413.

［16］Croswell JM，Ransohoff DF，Kramer BS. Principles of cancer screening：lessons from history and study design issues. Semin Oncol，2010，37（3）：202-215.

［17］Marcus PM，Bergstralh EJ，Fagerstrom RM，et al. Lung cancer mortality in the Mayo Lung Project：impact of extended follow-up. J Natl Cancer Inst，2000，92（16）：1308-1316.

［18］Lafata JE，Simpkins J，Lamerato L，et al. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev，2004，13（12）：2126 - 2132.

［19］World Health organization. Choosing Interventions that are Cost effective（WHO-CHOICE）. http：/ / www. who. int/choice/costs/CER_thresholds/en/index. html.

［20］Huang Y，Zhou K，Li H，et al. Knowledge，attitudes，and behaviour regarding breast cancer screening among women from different socio-economic regions in southwest China：a cross-sectional study. Asian Pac J Cancer Prev，2011，12（1）：203-209.

［21］Harris RP，Helfand M，Woolf SH，et al. Current methods of the US Preventive Services Task Force：a review of the process. Am J Prev Med，2001，20（3 Suppl）：21-35.

［22］Blake JG，Calonge N，Miller T，et al. Current processes of the U. S. Preventive Services Task Force：refining evidence-based recommendation development. Academia and Clinic，2007，147（2）：117-122.

［23］Zhao FH，Lewkowitz AK，Chen F，et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. JNCI，2012，104（3）：178-188.